Not a single reliable one.

Guidelines recommend diagnosing perimenopause in women over 45 based on symptoms and changes in your menstrual cycle, without lab tests, because a hormone like FSH fluctuates so much during this transition that one measurement can look completely normal one week and postmenopausal the next, in the same woman. Guidelines actually list several tests, including AMH, estradiol, and inhibin, that should not be used to diagnose perimenopause or menopause in women over 45. Testing has a real, narrower role in specific situations: confirming menopause in women aged 40-45, or investigating suspected premature ovarian insufficiency under 40.

What to know about this answer

The public debate sounds like a fight over whether to test at all, but within the source material almost nobody disputes that a single hormone test cannot diagnose typical perimenopause. The real disagreement is over whether testing has legitimate tactical uses in specific situations, like on hormonal contraception or to guide dosing.

What the research shows, and which source each finding rests on

NICE NG23 directs clinicians to diagnose perimenopause and menopause in otherwise healthy women over 45 on clinical grounds alone, vasomotor symptoms plus menstrual cycle changes, without laboratory tests, because FSH fluctuates considerably and results do not change management.

A[1]

NG23 restricts FSH testing to two situations: considering it to confirm menopause in women aged 40-45 with menopausal symptoms including a change in cycle, and in women under 40 with suspected premature ovarian insufficiency, where diagnosis requires elevated FSH on two samples plus the clinical picture.

A[1]

NG23 lists tests that should not be used to diagnose perimenopause or menopause in women over 45: anti-Mullerian hormone (AMH), inhibin A, inhibin B, estradiol, antral follicle count, and ovarian volume.

A[1]

The NICE quality standard (QS143) makes clinical diagnosis without laboratory tests in over-45s an explicit quality marker of good care.

A[1]

The international staging system for reproductive aging (STRAW+10) is built on menstrual bleeding criteria, not hormone levels; elevated FSH is only a supportive criterion for the late transition, with an explicit caution that values are assay-dependent.

A[2]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Test nothing; diagnosis is clinical

NICE NG23, mainstream menopause societies, and clinicians such as Dr. Jen Gunter and Dr. Corinne Menn

FSH fluctuates too much to inform diagnosis, results do not change management, and an abnormal-looking normal result can mislead in both directions, including the common error of being told your hormones are normal so it can't be perimenopause.

A[1]A[2]

Testing has legitimate tactical uses

some practicing clinicians, including Dr. Heather Hirsch, Dr. Felice Gersh, and Dr. Avrum Bluming

Some clinicians use FSH pragmatically alongside bleeding history, for example to help decide when a woman on combined contraception can safely stop it, or to help titrate estrogen dosing during treatment, while still agreeing that periods outrank any single lab value.

A[1]

What would settle it: A trial or decision-analysis testing whether adding any biomarker strategy to clinical diagnosis actually changes time-to-appropriate-treatment or outcomes in women over 45, and validated approaches for the genuinely hard cases such as hormonal contraception users.

What is really going on here

  1. Which tests are being ordered, and does a guideline actually recommend them for someone my age?
  2. Am I over 45 with typical symptoms, or under 40-45, where testing has a more legitimate role?

Questions for your doctor

  1. Given my age and symptoms, does a guideline actually call for hormone testing in my situation?
  2. If a test comes back normal, does that rule out perimenopause, or is that expected given how much hormones fluctuate?
  3. Am I on hormonal contraception, and if so, does that make any hormone test uninterpretable?
  4. What are you using instead of a blood test to reach a diagnosis - my cycle history, my symptoms, or both?

Questions with no answer yet

Would combining several imperfect biomarkers, such as FSH, AMH, and a symptom inventory, into one score do a meaningfully better job of identifying perimenopause than any one test alone, or clinical criteria by themselves?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: No guideline currently endorses a multimodal biomarker strategy for over-45s, and the studies that exist test each marker largely on its own. Whether a combined-score approach would add real value over clinical diagnosis has not been tested in a trial or decision-analysis.

What would test it: A trial or decision-analysis comparing a multimodal biomarker score against clinical diagnosis alone, measuring whether it changes time-to-appropriate-treatment or outcomes in women over 45.

For women who genuinely cannot be staged by bleeding criteria, such as those on hormonal contraception or after ablation, does any validated testing algorithm exist, or is this simply an unaddressed gap in current guidance?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The staging system explicitly states it cannot classify these groups by bleeding criteria alone, and current guidance offers no validated alternative algorithm for them. The practical answer in the field is reported as largely improvisational, built on individual clinical judgment rather than a tested protocol.

What would test it: Development and validation of a specific diagnostic algorithm for women who cannot be staged by bleeding criteria, tested against a reference standard.

Sources

  1. 1.NICE. Menopause: identification and management. NICE guideline NG23 (2015, updated November 2024), section 1.2; and quality standard QS143.Systematic review or guideline
  2. 2.Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10 (STRAW+10). Menopause 2012;19(4):387-95. · Systematic review or guideline

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions

Related guides